Wacker Chemie Valuation

Is 0NR4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0NR4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0NR4 (€69.66) is trading below our estimate of fair value (€184.98)

Significantly Below Fair Value: 0NR4 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0NR4?

Key metric: As 0NR4 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0NR4. This is calculated by dividing 0NR4's market cap by their current earnings.
What is 0NR4's PE Ratio?
PE Ratio28x
Earnings€124.30m
Market Cap€3.48b

Price to Earnings Ratio vs Peers

How does 0NR4's PE Ratio compare to its peers?

The above table shows the PE ratio for 0NR4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.2x
JMAT Johnson Matthey
20.8x28.6%UK£2.2b
CRDA Croda International
29.9x15.1%UK£4.9b
VCT Victrex
24.5x37.8%UK£751.3m
TET Treatt
21.6x15.3%UK£244.7m
0NR4 Wacker Chemie
28x37.0%€3.5b

Price-To-Earnings vs Peers: 0NR4 is expensive based on its Price-To-Earnings Ratio (28x) compared to the peer average (24.2x).


Price to Earnings Ratio vs Industry

How does 0NR4's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0NR4 28.0xIndustry Avg. 17.3xNo. of Companies13PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0NR4 is expensive based on its Price-To-Earnings Ratio (28x) compared to the European Chemicals industry average (17.3x).


Price to Earnings Ratio vs Fair Ratio

What is 0NR4's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0NR4 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28x
Fair PE Ratio26.7x

Price-To-Earnings vs Fair Ratio: 0NR4 is expensive based on its Price-To-Earnings Ratio (28x) compared to the estimated Fair Price-To-Earnings Ratio (26.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0NR4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€69.66
€114.40
+64.2%
12.5%€135.00€87.00n/a15
Nov ’25€77.91
€119.13
+52.9%
17.6%€178.00€87.00n/a16
Oct ’25€89.06
€124.47
+39.8%
14.6%€178.00€98.00n/a15
Sep ’25€87.16
€126.80
+45.5%
13.5%€178.00€100.00n/a15
Aug ’25€90.79
€127.87
+40.8%
14.2%€178.00€100.00n/a15
Jul ’25€98.92
€128.13
+29.5%
13.8%€178.00€103.00n/a15
Jun ’25€101.95
€127.00
+24.6%
14.3%€178.00€103.00n/a15
May ’25€101.51
€127.00
+25.1%
14.3%€178.00€103.00n/a15
Apr ’25€106.43
€122.73
+15.3%
15.2%€178.00€95.00n/a15
Mar ’25€104.59
€122.60
+17.2%
15.3%€178.00€100.00n/a15
Feb ’25€100.54
€122.60
+21.9%
15.3%€178.00€100.00n/a15
Jan ’25€113.89
€138.80
+21.9%
14.3%€178.00€108.00n/a15
Dec ’24€111.50
€144.67
+29.7%
13.4%€178.00€108.00n/a15
Nov ’24€109.98
€145.71
+32.5%
14.0%€178.00€111.00€77.9114
Oct ’24€136.57
€152.60
+11.7%
13.4%€187.00€111.00€89.0615
Sep ’24€136.32
€153.06
+12.3%
13.0%€187.00€111.00€87.1616
Aug ’24€140.15
€153.13
+9.3%
13.0%€187.00€114.00€90.7916
Jul ’24€124.84
€157.63
+26.3%
14.0%€193.00€114.00€98.9216
Jun ’24€124.59
€161.75
+29.8%
14.1%€202.00€114.00€101.9516
May ’24€137.79
€166.20
+20.6%
13.7%€202.00€114.00€101.5115
Apr ’24€148.56
€165.00
+11.1%
14.0%€202.00€114.00€106.4316
Mar ’24€149.19
€160.06
+7.3%
17.6%€202.00€104.00€104.5916
Feb ’24€144.65
€155.81
+7.7%
16.6%€185.00€104.00€100.5416
Jan ’24€120.00
€155.00
+29.2%
19.3%€210.00€104.00€113.8916
Dec ’23€123.10
€150.00
+21.9%
20.9%€210.00€104.00€111.5016
Nov ’23€117.91
€150.38
+27.5%
21.1%€210.00€104.00€109.9816

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies